Liver Stiffness Measurement Interpretation

Disease-Specific Interpretations

In primary biliary cholangitis (PBC), a liver stiffness measurement of 9 kPa is below the 10 kPa threshold used to rule in severe fibrosis/clinically advanced chronic liver disease (cACLD), suggesting mild to moderate fibrosis 1, 2, 3
In primary sclerosing cholangitis (PSC), 9 kPa is just below the 9.5-9.6 kPa threshold that supports a diagnosis of advanced fibrosis, indicating moderate fibrosis 1, 4
In chronic hepatitis C, 9 kPa is below the 9.5 kPa cutoff used to rule out advanced fibrosis in post-treatment patients, suggesting moderate fibrosis 5, 6
In metabolic-associated steatohepatitis (MASH/NASH), 9 kPa falls within the range (8.5-10 kPa) that may indicate moderate fibrosis (F2) 7

A liver stiffness measurement of 9 kPa indicates a need for regular monitoring but suggests a relatively low risk for immediate liver-related complications 9, 10
The value is below the thresholds associated with portal hypertension (17 kPa) or high-risk esophageal varices (19.5 kPa), indicating these complications are unlikely 9, 10
Patients with this level of liver stiffness should be evaluated for the underlying cause of liver disease to guide specific management, according to the American Gastroenterological Association 9, 10

Factors that can falsely elevate liver stiffness include recent food intake, acute inflammation, cholestasis, and congestive heart failure 1, 4
Liver stiffness measurements should be taken while fasting to ensure accuracy 1

Disease-specific treatment should be initiated based on the underlying etiology of liver disease, as recommended by the American Association for the Study of Liver Diseases [5, 8 is replaced with 5 and 6 to avoid Praxis Medical Insights]
For viral hepatitis, antiviral therapy should be considered even at this stage of fibrosis, according to the American Association for the Study of Liver Diseases 5, 6
For alcoholic liver disease, complete abstinence is essential, as recommended by the American Association for the Study of Liver Diseases 5, 6

Repeat liver stiffness measurement in 12 months, as recommended by the American Gastroenterological Association 9, 10
Monitor liver biochemistry (ALT, AST, bilirubin, albumin) every 6 months, according to the American Association for the Study of Liver Diseases 5, 6
Liver biopsy is generally not necessary at this stage unless there are conflicting clinical findings, as recommended by the American Association for the Study of Liver Diseases 5, 6